Splanchnic, Portal, Pelvic, and Miscellaneous Venous Disorders
Management begins by naming the venous bed and the consequence of delay: portal inflow and transplant or TIPS access in portal vein thrombosis, bowel viability in mesenteric venous thrombosis, hepatic outflow in Budd-Chiari syndrome, and symptom burden in pelvic venous disease. Anticoagulation is the usual first treatment for acute splanchnic thrombosis without bowel infarction; intervention is reserved for selected failure patterns, threatening anatomy, or reconstructable outflow obstruction.
Choose a chapter overview or a specialist discussion. Each recording follows this published edition.
General medical education, not patient-specific advice.
Choose an audio editionDefinition and presentation
Splanchnic, portal, and pelvic venous disorders encompass distinct anatomic territories with specific organ-threat profiles. Portal vein () threatens portal inflow, variceal bleeding control, and access for future transjugular intrahepatic portosystemic shunt () creation or liver transplantation . Mesenteric venous thrombosis () threatens bowel viability and typically presents with acute abdominal pain; the development of peritonitis, sepsis, or acidosis indicates progression to intestinal infarction . Budd-Chiari syndrome represents hepatic venous or caval outflow obstruction and leads to congestive liver failure and portal-hypertensive decompensation . Pelvic venous disease encompasses reflux or obstructive pathophysiology that threatens physical function and quality of life, presenting with chronic pelvic pain, dyspareunia, dysmenorrhea, vulvar or perineal varices, and lower-extremity varices of pelvic origin .
Porto-sinusoidal vascular disease and non-cirrhotic portal hypertension cause portal-hypertensive complications, including variceal bleeding, ascites, and hepatic encephalopathy, despite preserved synthetic liver function. Approximately 40% of patients with porto-sinusoidal vascular disease develop PVT within 5 years .
Diagnosis and classification
Radiologic diagnosis of splanchnic thrombosis specifies the involved segments (main portal vein, right or left branches, splenic vein, superior or inferior mesenteric vein, hepatic veins, or inferior vena cava). Classification defines the acuity (recent versus chronic), extent (partial versus occlusive, cavernous transformation), and clinical context (cirrhotic, non-cirrhotic, malignant, inflammatory, or procedure-related) .
Pelvic venous disorders
Pelvic venous disease includes ovarian or internal iliac reflux, iliac outflow obstruction, renal venous obstruction, or combinations. Pelvic congestion is therefore not synonymous with May–Thurner anatomy. Pelvic pain is multifactorial; venous findings require correlation with the symptom pattern and assessment for other pelvic causes. Published referral populations do not establish the population prevalence of symptomatic pelvic venous disease .
The Symptoms-Varices-Pathophysiology () classification describes symptom distribution, variceal reservoirs and the reflux or obstruction mechanism; it is not, by itself, proof that the venous finding causes pain :
- Symptoms (S0 to S3): graded by pelvic and extrapelvic distribution.
- Varices (V0 to V3): defines the specific venous reservoir.
- Pathophysiology (P): identifies the anatomic location, hemodynamic mechanism (reflux or obstruction), and etiology (thrombotic, nonthrombotic, or congenital).
Treatment thresholds and management logic
Management of splanchnic and pelvic venous disease targets the specific anatomic threat, balancing the prevention of venous extension against procedural and bleeding risks .
| Condition and scenario | Defining criteria | Preferred pathway | Citation |
|---|---|---|---|
| MVT without peritonitis | Stable exam, no bowel infarction | Immediate anticoagulation | |
| MVT with peritonitis | Suspected bowel infarction | Operative assessment and bowel resection | |
| MVT failing anticoagulation | Evolving symptoms, no peritonitis | Endovascular rescue (, lysis, stent) | |
| PVT in cirrhosis | Recent portal-trunk thrombosis exceeding 50% occlusion, symptomatic PVT, or liver-transplant candidacy | Anticoagulation under the Baveno VII population-specific recommendation (C.2) | |
| High-risk variceal bleed | Child-Pugh B with active bleeding, or Child-Pugh C 10 to 13 | Early or pre-emptive TIPS | |
| Budd-Chiari syndrome | Short hepatic vein or obstruction | Recanalization, angioplasty, or stenting | |
| Un-reconstructable Budd-Chiari | Outflow cannot be restored directly | Decompressive TIPS or | |
| Pelvic venous disease | Symptom and hemodynamic correlation | Symptom-directed embolotherapy or stenting |
- Defining criteria
- Stable exam, no bowel infarction
- Preferred pathway
- Immediate anticoagulation
- Citation
- Defining criteria
- Suspected bowel infarction
- Preferred pathway
- Operative assessment and bowel resection
- Citation
- Defining criteria
- Evolving symptoms, no peritonitis
- Preferred pathway
- Endovascular rescue (, lysis, stent)
- Citation
- Defining criteria
- Recent portal-trunk thrombosis exceeding 50% occlusion, symptomatic PVT, or liver-transplant candidacy
- Preferred pathway
- Anticoagulation under the Baveno VII population-specific recommendation (C.2)
- Citation
- Defining criteria
- Child-Pugh B with active bleeding, or Child-Pugh C 10 to 13
- Preferred pathway
- Early or pre-emptive TIPS
- Citation
- Defining criteria
- Short hepatic vein or obstruction
- Preferred pathway
- Recanalization, angioplasty, or stenting
- Citation
- Defining criteria
- Outflow cannot be restored directly
- Preferred pathway
- Decompressive TIPS or
- Citation
- Defining criteria
- Symptom and hemodynamic correlation
- Preferred pathway
- Symptom-directed embolotherapy or stenting
- Citation
Stepwise clinical decision logic
- Determine bowel viability in MVT. Immediate anticoagulation is the primary therapy for stable patients. Worsening pain, sepsis, acidosis, or peritoneal signs mandate operative exploration for bowel necrosis, removing the patient from the elective venous pathway .
- Integrate PVT management with portal hypertension goals. In cirrhotic PVT, anticoagulation decisions are coordinated with endoscopic variceal management, decompressive strategy, and transplant access requirements . The AGA expert update distinguishes specific PVT phenotypes in cirrhosis. Intestinal ischemia requires urgent anticoagulation. Without ischemia, observation with imaging every three months can be considered for recent thrombosis (less than six months) confined to intrahepatic branches or causing less than 50% occlusion of the main portal, splenic or mesenteric veins. Anticoagulation should be considered for recent thrombosis exceeding 50% occlusion or involving the main portal or mesenteric veins; progression, multiple vascular beds, transplant candidacy and thrombophilia increase the potential benefit of recanalization. Anticoagulation is not advised for chronic complete occlusion with cavernous transformation. Clinical stability alone is not an observation criterion.
- Follow a stepwise approach for Budd-Chiari syndrome. Anticoagulation and liver-directed therapy are paired with initial recanalization of short segment obstructions. Shunting is reserved for un-recanalizable anatomy or severe portal decompensation . Liver transplantation is the terminal salvage rung, reserved for failure of the stepwise sequence or fulminant hepatic failure.
- Require symptom-hemodynamic correlation for pelvic disease. Pelvic embolisation or iliac stenting are indicated only when imaging findings match the patient's specific symptom complex; anatomic narrowing or dilated veins on cross-sectional imaging do not justify intervention in isolation .
Medical therapy and anticoagulation
Intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin is the first-line treatment for acute MVT without peritonitis, facilitating rapid reversal if surgery or procedures are required . Long-term anticoagulation continues for at least 6 months following transient provoking factors, and is maintained indefinitely for idiopathic MVT or persistent thrombophilia.
Direct oral anticoagulants are indicated for selected patients with splanchnic vein thrombosis. They are avoided in the presence of advanced liver disease, severe renal dysfunction, high-risk bleeding, antiphospholipid syndrome, and in scenarios requiring rapid reversibility for procedural control .
In cirrhotic PVT, early anticoagulation prevents thrombotic extension, promotes recanalization, and maintains feasibility for TIPS and liver transplantation . For PSVD-associated PVT, Baveno VII recommends following the noncirrhotic PVT pathway (recommendation 9.28, C.1), not automatically importing cirrhotic PVT thresholds.
Endovascular and surgical intervention
Endovascular escalation in superior mesenteric venous thrombosis is a rescue therapy for patients failing anticoagulation or experiencing progressive bowel threat. Thrombectomy, catheter-directed thrombolysis, and stent placement achieve technical success in 75% of selected patients with an 88.9% 14-day primary patency and an 82% 5-year survival . Open bowel resection is required in 43.9% of acute MVT cases upon development of infarction; the 9.5% 30-day mortality reported in this series is the overall acute MVT figure, not the resection or transmural-infarction subgroup, whose mortality is higher .
Budd-Chiari endovascular therapy achieves a 98.9% overall technical success rate and 96.9% clinical success rate . Hepatic vein or inferior vena cava recanalization procedures demonstrate superior 5-year survival compared with TIPS or DIPS alone (97.9% versus 87.9%), establishing recanalization as the preferred initial intervention when technically feasible. The 5-year reintervention rate is 18.9%. In advanced or diffuse disease where direct recanalization cannot restore outflow, TIPS decompression is used; the hepatic venous pressure gradient is unreliable in Budd-Chiari because of the hepatic vein outflow block and is not used as the decision metric .
For pelvic-origin varices without pelvic symptoms, ESVS favors initial local treatment of the varices or escape points (IIa/C), not initial pelvic embolization (III/C). With pelvic symptoms requiring treatment and concordant venous disease, embolization should be considered for symptom improvement (IIa/B) .
Embolization targets reflux; stenting targets appropriately selected outflow obstruction. Mixed reflux and obstruction may require staged assessment rather than treatment of every visible abnormality. Incidental dilatation or compression is not a treatment indication. Counseling should distinguish technical occlusion from relief of the presenting symptoms and acknowledge the limitations of comparative evidence .
Surveillance and follow-up
Following acute MVT, clinical reassessment and repeat imaging monitor for failure of anticoagulation to halt progression to bowel infarction . Long-term follow-up adjusts the duration of anticoagulation based on transient factors, persistent thrombophilia, malignancy, recurrent thrombosis, and liver disease trajectory .
Post-procedural surveillance after Budd-Chiari reconstruction tracks restenosis, shunt dysfunction, progressive liver disease, and emergent portal-hypertensive complications, necessitating longitudinal care integrated with hepatology .
Follow-up in pelvic venous disease evaluates symptom response rather than purely venographic occlusion. Efficacy is assessed against the presenting symptom domain, variceal reservoir, and concurrent gynaecologic or urologic diagnoses, directing staged treatments when mixed reflux and obstruction are identified .
Areas of controversy
The superiority of hepatic vein recanalization over TIPS in Budd-Chiari syndrome relies on observational meta-analyses where selection bias directs recanalization toward less advanced disease .
The efficacy of endovascular rescue therapy for superior mesenteric venous thrombosis is derived from small, retrospective, single-center series subject to significant selection bias, limiting its generalizability outside expert referral centers .
PSVD-associated PVT is managed according to noncirrhotic PVT guidance. Whether anticoagulation should be used for primary PVT prevention in remains unresolved; Baveno VII makes no preventive recommendation (9.27, D.2) .
Direct oral anticoagulant applications in splanchnic vein thrombosis are supported by meta-analyses, but safety margins remain constrained by exclusions for advanced liver disease, bleeding risks, and drug interactions, precluding universal adoption .
Pelvic venous embolotherapy outcomes rely heavily on systematic reviews of observational data using varying symptom-response definitions and heterogeneous patient selection criteria .
Further reading
- Efficacy of embolotherapy for the treatment of pelvic congestion syndrome: A systematic review. (2024). Pelvic congestion embolotherapy evidence.
- Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. (2021). Anticoagulation evidence across splanchnic venous thrombosis.
References
- 1.Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. 2021.PubMed-indexed articleClinical practice guideline2020
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. 2021. doi:10.1002/hep.31646.
- 2.
- 3.
- 4.Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). 2021.PubMed-indexed articleClinical practice guideline2021
Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL). 2021. doi:10.1007/s12072-021-10189-4.
- 5.
- 6.
- 7.Nicoara-Farcau O, Rusu I, Stefanescu H, et al. Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease. World Journal of Gastroenterology. 2020.PubMed-indexed articleReview2020
Nicoara-Farcau O, Rusu I, Stefanescu H, et al. Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease. World Journal of Gastroenterology. 2020. doi:10.3748/wjg.v26.i22.3000.
- 8.
- 9.
- 10.Acosta S, Salim S. Management of Acute Mesenteric Venous Thrombosis: A Systematic Review of Contemporary Studies. Scandinavian Journal of Surgery. 2021.PubMed-indexed articleMeta-analysis / systematic review2021
Acosta S, Salim S. Management of Acute Mesenteric Venous Thrombosis: A Systematic Review of Contemporary Studies. Scandinavian Journal of Surgery. 2021. doi:10.1177/1457496920969084.
- 11.
- 12.de Franchis R, Bosch J, Garcia-Tsao G, et al. (Baveno VII Faculty) Baveno VII - Renewing consensus in portal hypertension. Journal of Hepatology. 2022.PubMed-indexed articleClinical practice guideline2022
de Franchis R, Bosch J, Garcia-Tsao G, et al. (Baveno VII Faculty) Baveno VII - Renewing consensus in portal hypertension. Journal of Hepatology. 2022. doi:10.1016/j.jhep.2021.12.022.
- 13.Mukhiya G, Zhou X, Han X, et al. Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis. Scientific Reports. 2022.PubMed-indexed articleMeta-analysis / systematic review2022
Mukhiya G, Zhou X, Han X, et al. Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis. Scientific Reports. 2022. doi:10.1038/s41598-022-20399-x.
- 14.
- 15.
- 16.AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review. 2025.PubMed-indexed articleClinical practice guideline2025
AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review. 2025. doi:10.1053/j.gastro.2024.10.038.
- 17.
- 18.
- 19.Direct oral anticoagulants for the treatment of splanchnic vein thrombosis - A systematic review and meta-analysis. 2023.PubMed-indexed articleMeta-analysis / systematic review2023
Direct oral anticoagulants for the treatment of splanchnic vein thrombosis - A systematic review and meta-analysis. 2023. doi:10.1016/j.thromres.2023.06.003.
- 20.
- 21.Consensus Statement on the Management of Nonthrombotic Iliac Vein Lesions From the VIVA Foundation, the American Venous Forum, and the American Vein and Lymphatic Society 2024-08.PubMed-indexed article2024
Consensus Statement on the Management of Nonthrombotic Iliac Vein Lesions From the VIVA Foundation, the American Venous Forum, and the American Vein and Lymphatic Society 2024-08. doi:10.1161/CIRCINTERVENTIONS.124.014160.
- 22.European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs 2022-01-11 online; 2022-02 issue.PubMed-indexed article2022
European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs 2022-01-11 online; 2022-02 issue. doi:10.1016/j.ejvs.2021.12.024.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.